Navoximod

Navoximod (GDC-0919; NLG- 919) is a potent IDO (indoleamine- (2,3) -dioxygenase) pathway inhibitor with Ki/EC50 of 7 nM/75 nM.

Product Specifications

CAS Number

[1402837-78-8]

Product Name Alternative

GDC-0919; NLG-919

UNSPSC

12352005

Hazard Statement

H315, H319

Target

Indoleamine 2,3-Dioxygenase (IDO)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Navoximod.html

Purity

99.99

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O[C@H](CC1)CC[C@]1([H])[C@H](O)C[C@@H]2N3C(C4=C2C(F)=CC=C4)=CN=C3

Molecular Formula

C18H21FN2O2

Molecular Weight

316.37

Precautions

H315, H319

References & Citations

[1]Mario R. Mautino, et al. Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO) -pathway inhibitor drug candidate for cancer therapy. AACR 104th Annual Meeting 2013; Apr 6-10, 2013.|[2]Li M, et al. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J Immunother Cancer. 2014 Jul 7;2:21.|[3]Chen Y, et al. An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Nat Commun. 2016 Nov 7;7:13443.